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last 45 days, there have been a 
number of major developments 
which have been shared with the 
physician community at many 
different levels. At this time, in 
this portion of Medical Staff 
Progress Notes, I would just like to 
briefly review some of them: 
• The integrated delivery 
system (IDS) for Lehigh Valley 
Hospital was announced by a 
special communiqu~ to the 
physicians and then ultimately by 
The Morning Call on May 25, 
199 5. The following hospitals are 
part of this integrated delivery 
system: Hazleton St. Joseph 
Medical Center, Hazleton General 
Hospital, Gnaden Huetten 
Memorial Hospital, Muhlenberg 
Hospital Center, Lehigh Valley 
Hospital, Doylestown Hospital, 
and Grand View Hospital. The 
Penn State Medical Center at 
Hershey will contract with us for 
special services in the following 
year and be part of this network 
as well. The important 
distinction between this network 
and other competing networks in 
the Lehigh Valley is that our 
integrated delivery system is not a 
merger of assets. This is a "hand 
holding'' relationship among 
administrations and physicians 
for health care in the Valley. 
Certain economies of scale will 
benefit each of these different 
hospitals in the purchasing of 
supplies and technology in the 
care of their patients. In time, 
they will all be connected by 
information services to Phamis 
Last Word so that blood testing, 
radiologic reports and admission 
history and physical exams can 
easily be accessed by all 
physicians in the network. In 
time, we hope that the different 
hospitals will also be collaborating 
through IP NPHO organizations 
which will allow the network to 
compete with managed care 
contracts throughout the Lehigh 
Valley. On this later point, our 
own IP NPHO through Valley 
Preferred is aggressively seeking 
(Continued on Page 2) 
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small businesses, including private 
practice physician offices, to offer 
he3.Ith care insurance and other 
benefits at reduced cost. Of the 
80 presentations made, 52 have 
signed on at this time. Currently, 
the PHO has acquired 17,000 
covered lives and continues to 
grow rapidly, well ahead of 
schedule. A recent IPA Board 
meeting has included that 
quarterly meetings of the 
IPNPHO membership will begin 
in order to provide more timely 
updates to our physicians on staff. 
• Information Services continues 
to make strides in improving 
Phamis for physicians. The 3.1 
upgrade of our current system has 
been accepted and over the next 
12- 14 months will be installed 
throughout the network. Lehigh 
Magnetic Imaging has been 
brought up to have its reports for 
inpatients put on the Phamis 
terminals. LMIC outpatient 
reports were also added to Phamis 
as of June 19, 1995. We 
continue to try to improve report 
turnaround so that Phamis 
Last Word will have reports up on 
the system electronically within 
24 hours. This project will greatly 
be improved when voice 
recognition technology has been 
perfected, which we anticipate 
will occur some time within the 
next year. 
• The re-engineering of our floors 
under the system of patient 
centered care is well underway for 
7 A and 7B, with 6B and 6C to 
follow soon afterward. The 
details of patient centered care 
have been shared in previous 
Medical Staff Progress Notes. We 
continue to remain optimistic 
that this system will offer better 
care of our patients, better 
communication between nurses 
and physicians, and ultimately 
obtain better patient satisfaction 
throughout the hospital. 
• The functional plan for the 
hospital has been studied in a 
collaborative fashion for almost 
two years. The conclusion of this 
functional plan will be presented 
to the Board this month and 
includes a plan for building 
projects and structural redesign tq 
occur over the next three years. 
The details of this project have 
been presented to Senior 
Management Council, Med Exec, 
and at the June 12 quarterly 
meeting of the medical staff. In 
brief, the major focus of this 
building campaign includes the re-
design of our floors selectively in a 
patient centered care approach 
and the building of a new 
ambulatory care wing to the 
hospital, to be located between 
MOB I and the main hospital 
building. This ambulatory care 
building will allow our patients 
easy access to a single location for 
outpatient testing, which 
(Continued on Page 3) 
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currently takes place at several 
locations within the matrix of a 
fairly complex Cedar Crest site. 
In addition, this will allow for 
appropriate expansion of the 
emergency room and 
inpatient/outpatient radiologic 
services to meet the needs of 
consolidation of the 17th & Chew 
site inpatient services to the 
Cedar Crest site, including 
pediatrics, psychiatry, and OB. 
• On June 3, 1995, 63 physicians 
from our medical staff met to 
discuss the topic of "How Do We 
Get There From Here?" This was 
a forward thinking, directive 
generating group that worked for 
over five hours to develop an 
understanding of eight key issues 
and determine measurable · 
standards for obtaining our 
medical staff goals that were 
previously published. The details 
and prioritization of this retreat 
group have been shared with 
Senior Management Council, 
Med Exec, and the Board of 
Trustees. We plan to give 
quarterly updates to the medical 
staff regarding the progress in 
obtaining those goals with a full 
assessment being initiated in 
June, 1996. 
• The emergency room re-design 
team consisting of Ron Lutz, Jim 
McHugh, Tony Werhun, Bev 
Snyder, Sue Durkin, Dawn 
Yenser, Bany Michneck, Joseph 
Rycek. and Rick Shurgalla have 
helped to delineate the problems 
and inefficiencies of our current 
system. The appropriate financial 
resources have been allocated to 
provide a short term gap 
improvement in the way our ER 
functions over the next year. A 
search committee consisting of 
Michael Rhodes (Chair), Ron 
Lutz, Mary Kinneman, Carol 
Bury, Chuck Hoover, Bob 
Laskowski, Jack Nuschke, Mark 
Osborne, Susan Wiley, Joe Fassl, 
Bob Miller, Kym Salness, Judee 
VonSeldeneck and Carol 
Voorhees have been charged to 
find a new chairperson of the 
Department of Emergency 
Medicine to replace Dr. Lutz, who 
stepped down in April, 199 5. We 
look forward to both the short 
term improvement that this 
committee can design and the 
long term improvement which can 
only be enacted with the 
functional plan. 
• Lastly, just a reminder to you of 
the importance of our Medical 
Staff/Administrative Exchange 
Sessions which occur the third 
Thursday of every month in the 
John and Dorothy Morgan 
Cancer Center, Conference Room 
1, Side B. The topic for the June 
meeting was the medical staff 
manpower plan, with specific 
delineation on how slots are 
decided for divisions and 
departments. The topic for the 
July meeting, schedule for July 20, 
will be Lehigh Valley Physician 
Group-- its current status. 
Sincerely, 
~C'. e-.~~ 
John E. Castaldo, MD 
President, Medical Staff 
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Site and Facilities Updat~ 
Cedar Crest & 1-78 
Lehigh Valley Hospital has begun 
extensive renovations to the main 
lobby at Cedar Crest & 1-78. 
The renovation project, which will 
continue through early August, has 
transformed the reception and 
entrance areas into a series of 
construction tunnels. The tunnels 
have been erected to facilitate the 
project while allowing access to the 
main elevators, Admissions, the 
GI/Endoscopy unit, and the cafeteria. 
The new lobby will extend from its 
existing location to space now 
occupied by the cafeteria conference 
room. 
As illustrated below, the project will 
be completed in phases and include: 
• extensive renovations to the Tree 
Top Shop which will be closed 
through mid-July 
( 
• the installation of a stone floor and 
the elevation of the ceiling in the 
hallway that links the lobby to the 
chapel and ancillary services; and 
• the installation of a stone floor in 
the vestibule, the area between the 
automatic doors at the entrance. 
During this part of the project, 
patients, staff, and visitors will be 
directed to exit the hospital via 
Stairwell 4 (parallel to the main 
entrance). 
With its bright new lighting, 
comfortable furnishings, and ease of 
access, the new lobby should prove 
to be wann and inviting to patients 
and staff alike. 
~~JL~¥:-~1"~~, Conference 
PHASE I 
Tunnels to be 
construcledr-tH---J.-!htiloo',l' 
6/1/95 
To be removed 
on or about 
7/15/95 
PHASE 2 
AI limes, during 
Phase 2, entrance will 
be restricted to one 
way traffic. hit will 
be thru Stairwell /14. 
dining room to 
close permanently. 
New area to be 






Gift Shop will 
close for 
renovation 
mid June ,!==.!I==-:!:!;;> 
thru 
mid July 
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News from the Pharmacy 
Accelerated ("Front 
Loaded") vs Standard 
Dosing Regimens for 
Alteplase (rTPA) 
Several thrombolytic therapy 
options exist for Acute MI 
including Streptokinase and 
Alteplase (rTPA). The FDA has 
recently approved the accelerated 
dosing regimen of rTP A in which 
the total dose is infused over 1.5 
hours. In comparison, the 
standard dosing regimen is 
administered over three hours. 
Alteplase requires dosage 
adjustment for patients weighing 
less than 65Kg ( 143 lbs) not to 
exceed a total dose greater than 
1.25mgll<g. 
The recent FDA approval of 
accelerated TPA dosing is dosed 
with a 15mg bolus followed by 
. 7 5mgll<g (max 50mg) over 30 
minutes followed by .5mWI<g 
(max 35mg) over 60 minutes. At 
Lehigh Valley Hospital, the 
Department of Medicine and 
Division of Cardiology, in 
conjunction with the Pharmacy 
and Therapeutics Committee, 
have instituted weight dosing for 
both TPA regimens for patients 
less than 65Kg ( 143 lbs) not to 
exceed a total dose of 1.25mgll<g. 
For example, a 60KG patient can 
receive one of the following TPA 
regimens: 
Standard Regimen 
Total dose 1.25mw'Kg = 7 5mg 
10% IV bolus = 7 .5mg 
50% IV over first hour = 37 .5mg 
20% IV over second hour = 15mg 
20% IV over third hour = 15mg 
Accelerated Regimen 
Total dose 1.25mgll<g = 7 5mg 
15% IV bolus= 11mg 
50% IV over 30 minutes = 
37.5mg 
35% IV over 60 minutes= 
26.5mg 
Please note that if this example 
patient was not weight dosed at 
1.25mgll<g total dose, 95mg 
would be received. Adjusting the 
dose for less that 65Kg patients 
appears to decrease the incidence 
of serious bleeding events after 
rTPA therapy. Ongoing 
monitoring of all thrombolytic 
therapy in AMI at Lehigh Valley 
Hospital is in progress to evaluate 
our incidence of bleeding events. 
As the Acute MI pathway is 
developed, pre-printed physician 
order sheets for chest pain and 
lytic therapy will be available and 
include all dosing regimens for 
Streptokinase and Alteplase. 
If you have any questions or need 
assistance with dosing, please 
contact the Pharmacy at 
402-8887 or 402-2250. 
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Ambulatory Surgery Unit Pre-Admission 
Processing 
Because of increasing demand and 
patient requests, the Ambulatory 
Surgery Unit pre-admission 
processing area at 17th & Chew 
recently expanded hours and 
appointment times for patient 
convenience. 
Pre-admission visits will be 
scheduled for all Ambulatory 
Surgery Unit patients to provide 
time for an anesthesia visit and 
avoid delays on the day of the 
procedure. 
As before, a pre-admission visit 
appointment time may be 
completed at the time of OR 
scheduling. In those instances 
when that is not accomplished, 
those patients will be contacted to 
schedule an appropriate time for 
their pre-admission visit. 
The expanded hours of operation 
include: 
Monday, Tuesday and 
Wednesday- 8 a.m. to 2 p.m. 
Thursday - 1 to 7 p.m. 
Friday - 7 a.m. to 1 p.m. 
Unscheduled visits to pre-
admission processing will be 
accommodated through 
scheduling as time permits, within 
the designated times listed above. 
In these instances, the patient will 
be assigned specific appointment 
time. 
If you have any questions or 
concerns, please contact Barbara 
Frantz, Director, Patient Care 
Services, at 402-3432. 
Mad Exec News 
• A special welcome to 
George I. Chovanes, MD, 
Oscar A. Morffi, MD, 
Alexander D. Rae-Grant, MD, 
and Kamalesh T. Shah, MD, 
who were recently elected 
members at-large of the 
Medical Executive Committee. 
• A special ''Thank You" to 
Robert B. Doll, MD, John D. 
Farrell, MD, Thomas A. 
Hutchinson, MD, and Mark C. 
Lester, MD, for their dedication 
and service to the medical 
staff as members of the 
Medical Executive Committee. 
• Congratulations to Robert X. 
Murphy, Jr., MD, who was 
recently elected AMA HMSS 
representative. 
Attention E-mail Users 
Due to the high volume of e-mail 
usage, physicians are reminded 
to check their e-mail on a 
regular basis and to delete those 
messages and files which are 
not needed in order to free up 
space on the system 1 
II 
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Auto Faxing to Physician Offices 
The Medical Record Department, 
in conjunction with Information 
Services, has the capability to 
electronically provide facsimile 
copies of medical record reports 
(histories and physicals, discharge 
summaries, operative reports, 
consultations, and cath reports) to 
attending, family, and referring 
physician offices at the time of 
transcription. 
To request access to this service, 
contact Susan Cassium, 
Supervisor, Operations, at 
402-8330, and provide her with 
the facsimile number to which 
reports should be forwarded. 
Please note that the facsimile 
must be accessible 24 hours a day. 
Individual physicianNgroups 
should also consider the volume 
of reports prior to requesting this 
service. Larger volumes might 
require a designated facsimile for 
transcription reports only. 
Physicians not participating in 
this project will continue to 
receive copies either by delivery or 
mail. Additional copies of reports 
will also continue to be mailed as 
per physician request. 
For additional information, 
contact Susan Cassium at 
402-8330. 
Co-Medical Directors Appointed for Transitional 
Skilled Unit 
David P. Carney, MD, general 
internist, and Howard A. 
Silverman, MD, family 
practitioner, have been appointed 
as the Co-Medical Directors of 
the Transitional Skilled Unit. In 
this position, they will be 
responsible for assuring that the 
care provided in the unit meets all 
regulatory requirements, that the 
clinical care is appropriate to the 
facility, and that it is provided at 
the highest standard. 
Sincere appreciation goes out to 
Jane Dorval, MD, Chief, 
Division of Physical Medicine & 
Rehabilitation, who has 
functioned as the Int~rim Medical 
Director of the TSU during its 
first phase. She has done a 
terrific job of assuring that the 
unit got off on the right foot. 
Thank you, Jane. The Medical 
Staff is deeply in your debt. 
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Congratulations! 
David G. Beckwith, PhD, Vice 
President and Clinical Director, 
Health Network Laboratories, was 
recertified by the American Board 
of Medical Microbiology and 
granted active status through 
June, 1998. 
George F. Carr, DMD, Vice 
Chairperson, Department of 
Dentistry, was recently elected 
President of Lehigh County 
Dental Society. 
George A. Kirchner, DDS, 
prosthodontist, was elected 
Speaker of the House for the 
Pennsylvania Dental Association. 
In addition, Dr. Kirchner, along 
with Charles J. lncalcaterra, 
DMD, Assistant Program 
Director, Dental Residency, and 
Thomas J. McKee, DMD, 
periodontist, served as delegates 
for the Pennsylvania Dental 
Association Annual Meeting held 
May 18 to 21 in Pittsburgh. 
Stephen K. Klasko, MD, Acting 
Chairperson, Department of 
Obstetrics and Gynecology, 
received an award for his oral 
abstract, "Reduction of Stress and 
Prediction of Burnout in an 
Obstetrics-Gynecology Residency 
Program," which he presented at 
the Annual Meeting of the 
Council on Resident Education in 
Obstetrics and Gynecology and 
the Association of Professors in 
Gynecology and Obstetrics, held 
March 8-11 in Orlando, Fla. 
Linda L. Lapos, MD, colon and('" 
rectal surgeon, was elected to 
Fellowship in the American 
Society of Colon and Rectal 
Surgeons during the Annual 
Meeting held May 7-12 in 
Montreal. 
Thomas D. Meade, MD, 
orthopedic surgeon, recently 
returned from Ft. Lauderdale, 
Fla., with two top ten medals 
from the 1995 United States 
Masters Swimming National 
Championship. He participated 
in butterfly, free-style, and relay 
events. 
On June 5, 3C was divided 
into three areas on the 
computer. Inpatients will 
appear on the computer as 
3C. Same day surgical admit 
patients or day of procedure 
admission patients (DOPA) 
will appear as SDA. Same 
day admit patients, directs, 
and transfers scheduled for 
procedures scheduled in the 
Cardiac Cath Lab will be 
labelled CV. This change will 
enable 3C and the Cath Lab to 
obtain lab labels. Please 
remember - if the patient 
location on the computer is 
3C, SDA, or CV, these 
patients will physically be 
located on 3C. If you have 
any questions regarding this 
issue, please contact Julia 
Clelland at 402-8249. 
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Papers, Publications and Presentations 
A poster session titled 
"Comparison of Vidas-RSV and 
Ba.xter-Bartels DFA-RSV with 
Cell Culture for Detection of 
Respiratory Syncytial Virus from 
Nasal Aspirates" by 
microbiologists Sandra Todd, 
Georgia Colasante, and David G. 
Beckwith, PhD, was presented at 
the American Society for 
Microbiology hdd recently in 
Washington, DC. 
"Iliac Compression Syndrome 
Treated with Stent Placement," 
written by Alan Berger, MD, 
Chief, Division of Vascular 
Surgery, James W. Jaffe, MD, 
Chief, Division of Cardiovascular/ 
Interventional Radiology, and 
Terry N. York, DO, former 
Radiology fellow, was published 
in the March 1995 edition of the 
f{!Urnal of Vascular Surgery. 
George F. Carr, DMD, Vice 
Chairperson, Department of 
Dentistry, presented 
"Biomechanical Influences on 
Dental Implants in the Oral 
Environment" to the New York 
University Implant Study Club in 
May. 
Houshang G. Hamadani, MD, 
psychiatrist, presented a paper, 
"Teaching Non Physician Mental 
Health Workers Clinical 
Psychiatry and 
Psychopharmacology Abroad," at 
the American Psychiatric 
Association Annual Meeting held 
recently in Miami, Fla. He was 
also appointed to the American 
Psychiatric Association 
Psychiatric Research Network. 
Peter A. Keblish, MD, Chief, 
Division of Orthopedic Surgery, 
was the moderator, guest surgeon, 
and guest speaker at the UClA 
Learning Center in late April, 
hosted by Dr. Douglas Kilgus, 
Associate Professor of Orthopedic 
SurgerynUCLA. TheUCLA 
West Coast Learning Center for 
Mobile Bearing Knee Arthroplasty 
is a West Coast Extension of the 
Lehigh Valley Hospital Learning 
Center, directed by Dr. Keblish 
for the past five years. Lehigh 
Valley Hospital has been a major 
Center for total joint replacement 
evaluation for the past 15 years 
and a leader in clinical research 
on Mobile Bearing Total Knee 
Replacement. The Orthopedic 
Learning Center concept is 
designed for demonstrating and 
teaching post-graduate education 
on newer concepts in orthopedic 
surgery. Dr. Keblish has directed 
Learning Centers in several 
international cities, the latest in 
Rio de Janeiro in March. 
William L. Miller, MD, Vice 
Chairperson and Program 
Director, Department of Family 
Practice, will be one of two 
plenary speakers at the Primary 
Care Research Methods and 
(Continued on Page 10) 
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Statistics Conference to be held 
December 1-3 in San Antonio, 
Texas. Dr. Miller shares the 
honor of plenary speaker with 
Thomas S. Inui, ScM, MD, 
Professor and Chairman, 
Ambulatory Care and Prevention, 
Harvard Medical School and 
Harvard Community Health Plan. 
The theme of the conference is 
multimethods research. 
Glen L. Oliver, MD, 
ophthalmologist, was a Visiting 
Professor of Ophthalmology at 
Grand Rounds at Penn State 
University, Hershey Medical 
School on May 31. During the 
afternoon, he participated in case 
presentations by the residents for 
discussion followed by a lecture 
on the new ocular syndrome, 
"IRV AN." In the evening, he gave 
the Grand Rounds lecture on his 
early investigational work in 
establishing the hereditary pattern 
of Familial Exudative 
Vitreoretinopathy (FEVER). 
James F. Reed, PhD, Director of 
Research, and Barbara 
Salvadore, MS, Administrative 
Director, Department of Family 
Practice, have been invited to 
present their abstract, 
"Development of a Clinical 
Pathway for Adult Community 
Acquired Pneumonia," at the 
Gerontological Health Section for 
the American Public Health 
Association's 123rd Annual 
Meeting to be held on October 30 
in San Diego, Calif. The theme 
of the annual meeting is "Decisioh 
Making in Public Health: 
Priorities, Power and Ethics." 
Toll-Free COLA Line 
Physicians and their staffs can 
get quick answers to in-office 
testing questions by calling the 
Commission on Office Laboratory 
Accreditation (COLA), Silver 
Spring, MD, at (800) 298-8044. 
The new service is available 
throughout the United States on 
weekdays from 9 a.m. to 5 p.m. 
<Esn. 
caners are conneded diredly to 
the COLA Customer Service 
Center, which is staffed by 
medical technologists who can 
provide information to office 
laboratory staffers. The new 
service is made possible by a 
cooperative agreement between 
COLA and the Centers for 
Disease Control and Prevention. 
The agreement will also enable 
COLA to condud an educational 
needs assessment and analysis 
of more than 7,000 office labs, 
develop fad sheets, and put 
together a database to determine 
laboratory testing complexity. 
The toll-free number, adivated 
January 15, replaces the long 
distance CLIA hotline, which was 
deadivated last fall. 
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The July Medical Staff/ 
Administrative Exchange 
Session will be held on Thursday, 
July 20, beginning at 5:30p.m., 
in Conference Room 1, Side B, of 
the John and Dorothy Morgan 
Cancer Center. 
It is of paramount importance 
that as many physicians as 
possible attend these sessions to 
participate in the exchange of 
information about important 
topics in a timely manner. 
Topics to be discussed will be 
posted throughou( the hospital 
prior to the session. 
For more information, contact 
John E. Castaldo, MD, Medical 
Staff President, through Physician 
Relations at 402-9853. 
Psychiatry Grand Rounds 
Family Psychiatry will be 
presented by Michael Kerr, MD, 
Director of Georgetown Family 
Center, Washington, DC, on 
Thursday, July 20, beginning at 
noon in the Auditorium at 17th 
&Chew. 
As lunch will be provided, pre-
registration is requested. For 
more information or to register, 
contact Usa Frick in the 
Department of Psychiatry at 
402-2810. 
The Department of Family 
Practice is delighted to 
announce that it has been 
accredited for two and one-
half years by the Residency 
Review Committee for the 
Lehigh Valley Hospital Family 
Practice Residency Training 
Program. The first residents 
will begin in June, 1996. Much 
of the credit for the successful 
accreditation goes to Will 







The Who's New section of Medical · 
Staff Progress Notes contains an 
update of new appointments, 
address changes, newly approved 
privileges, etc. Please remember 
that each department or unit is 
responsible for updating its 
directory, rolodexes, and 
approved privilege rosters. 
Medical Staff 
Appointments 
Robert K. Bryan, DDS 
Lehigh Valley Orthodontics 
(Dr. William Bryan) 
ROMA Building 
1605 N. Cedar Crest Blvd. 
Suite 519 
Allentown, PA 18104-2351 
(Address effective June 26, 1995) 
(610) 435-2788 
Department of Dentistry 
Division of Orthodontics 
Provisional Courtesy 
Raymond A. Durkin, MD 
Cardiology Care Specialists 
(Dr. Morris) · 
3340 Hamilton Blvd. 
Allentown, PA 18103-4598 
(610) 433-6442 
FAX: (610) 776-6645 
Department of Medicine 
Division of Cardiology 
Provisional Active 
Thomas J. Durkin, Jr., MD 
Family Pediatricians ( 
(Dr. Kean) 
Allentown Medical Center 
401 N. 17th Street, #109 
Allentown, PA 18104-6804 
(610) 435-6352 
FAX: (610) 435-8950 
Department of Pediatrics 
Division of General Pediatrics 
Provisional Active 
Herbert C. Hoover, Jr., MD 
Chairperson, Department of 
Surgery 
Lehigh Valley Hospital 
Cedar Crest & 1-7 8 
Allentown, PA 18105-1556 
(610) 402-8338 
FAX: (610) 402-1667 
Department of Surgery 
Division of General Surgery 
Provisional Active 
Karen M. Matz, MD 
College Heights OBGYN 
Associates, PC 
(Dr. Hutchinson) 
3131 College Heights Blvd. 
Allentown, PA 18104-4899 
(610) 437-1931 
FAX: (610) 433-8791 
Department of Obstetrics and 
Gynecology 
Division of Primary OBGYN 
Provisional Active 
(Continued on Page 13) 
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Renee E. V alach, MD 
Inpatient Pediatric Unit 
Lehigh Valley Hospital 
17th &Chew 
Allentown, PA 18105-7017 
( 61 0) 402-2550 
. FAX: (610) 402-9674 
Department of Pediatrics 
Division of General Pediatrics 
Provisional Limited Duty 
Change of Address 
William J. Bryan, DDS 
Lehigh Valley Orthodontics, PC 
ROMA Building 
1605 N. Cedar Crest Blvd. 
Suite 519 
Allentown, PA 18104-2351 
(Effective June 26, 1995) 
Tamar D. Earnest, MD 
Department of Surgery 
Lehigh Valley Hospital 
Cedar Crest & I-7 8 
Allentown, PA 18105-1556 
(610) 798-5026 
FAX: (610) 432-7477 
Status Change 
Walter J. Dex, MD 
. Department of 
Radiology/Diagnostic Medical 
Imaging 
Division of Diagnostic Radiology 
From Active to Emeritus Active 
Alan H. Schragger, MD 
Department of Medicine 
Division of Dermatology 
From Active to Emeritus Active 
Resignation 
Robert V. Cummings, MD 
Department of Obstetrics and 
Gynecology 




Harry S. Good, MD 
Department of Surgery 
Division of General Surgery 
Honorary 
Allied Health Professionals 
Appointments 
S. Elizabeth Abrams, CRNA 
Physician Extender 
Professional- CRNA 
(Allentown Anesthesia Associates, 
-Dr. Maffeo) 
Gina M. Brown 
Physician Extender 
Technical- MA 
(Cardiology Care Specialists- Dr. 
Zelenkofske) 
(Continued on Page 14) 
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Additional Privileges 
Dennis Frederick, PA-C 
Physician Assistant 
(Allen Neurosurgical Association, 
Inc.) 
Prescriptive Privileges 
Michael Kramer, PA-C 
Physician Assistant 
(Allen Neurosurgical Association, 
Inc.) 
Prescriptive Privileges 
George M. Perovich, EdD 
Associate Scientific 
Psychologist 
Special Privileges for 
Psychologists 
Population 
- Children (under age 13) 
-Adults ( 1 9 and older) 
- Geriatric ( 60 and above) 
Clinical Assessment Privileges 
- Forensic assessment 
- Vocational/Educational 
assessment 
Clinical Treatment Privileges 
- Pain management 
- Rehabilitation services 
· .:; 'Sexual Dysfunction Therapy 
Resignation 
Phillip L. Hansell, PA-C 
Physician Extender 
Physician Assistant 
(Panebianco-Yip Heart Surgeons) 
( 
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LEHIGH VAUEY HOSPITAL 
Chajroersons of Qepartments 
and Chiefs of pjyjsjons and Sections 
and Unjt!Lab Medjcal Directors 
1995-1996 
(Effective July 1, 1995) 
John E. Castaldo, MD 
Robert X. Murphy, Jr., MD 
Joseph A. Candio, MD 
Ronald A. Lutz, MD 
John J. Shane, MD 
















Alphonse A. Maffeo, MD 
Ramon J. Deeb, MD 
Eric J. Marsh, DMD 
Scott A. Gradwell, DMD 
Dominic P. Lu, DDS 
Charles J. lncalcaterra, DMD 
Mark Eisner, DMD 
Charles A. Kosteva, DDS 
Sara Karabasz, DMD 
Hugh J. O'Donnell, DDS 
Scott A. Gradwell, DMD 
Peter T. Davis, DDS 
Russel S. Bleiler, DDS 
Ronald A. Lutz, MD 
James G. McHugh, MD 
Ronald A. Lutz, MD 









Acting Vice Chairperson 
Program Director 








faMILY PRACIICE Headley S. White, Jr, MD Chairperson 
William L. Miller, MD Vice Chairperson/ 
Program Director 
Diyjsjons/Sactjons .c.t!it!l 
Occupational Medicine Carmine J. Pellosie, DO 
Home Care Fred D. Fister, MD 
MEDICINE John P. Fitzgibbons, MD Chairperson 




Mark H. Mishkin, MD Student Mentor 
Chief Medical Resident Michael Schlechter, MD 
Divisions/Sections .cblm Associate Chjef 
Allergy Howard A. Israel, MD 
Ambulatory Care Yehia Mishriki, MD 
Cardiology D. Lynn Morris, MD Norman H. Marcus, MD 
Dermatology Arthur C. Sosis, MD 
Endocrinology/Metabolism Larry N. Merkle, MD 
Gastroenterology Carl F. D'Angelo, MD 
General Internal Medicine David M. Caccese, MD John D. Nuschke, MD 
Geriatrics Francis A. Salerno, MD David P. Carney, MD 
Hematology/Medical Oncology (Vacant) 
Infectious Diseases Luther V. Rhodes, Ill, MD 
Nephrology Joseph C. Guzzo, MD 
Neurosciences Peter J. Barbour, MD 
Physical Medicine 
and Rehablltation Jane Dorval, MD Joseph J. Grassi, MD 
Pulmonary Joseph E. Vincent, MD 











Pelvic Reconstructive Surgery 





















Stephen K. Klasko, MD 
Ernest Y. Normington, MD 
Stephen K. Klasko, MD 
James Balducci, MD 
James Balducci, MD 
Vincent Lucente, MD 
Sergio Perticucci, MD 
Vincent Lucente, MD 
Bruce I. Rose, MD 
Gregory Radio, MD 
John J. Shane, MD 
Raymond A. Rachman, MD 
John J. Shane, MD 
Isidore Mihalakis, MD 
William Dupree, MD 
(Vacant) 
John D. VanBrakle, MD 
Dennis W. Kean, MD 
Jerome Dunn, MD 
Sarah J. Fernsler, MD 
Louis W. Hansrota, MD 
Karen E. Senft, MD 
Oscar A. Morffi, MD 
lan M. Gertner, MD 
Martha A. Lusser, MD 
Robert W. Miller, MD 
Michael W. Kaufmann, MD 
Susan D. Wiley, MD 
John F. Campion, MD 
Acting Chairperson 
Vice Chairperson, Medical Affair 
Vice Chairperson, Education/ 











Adult Inpatient P1ychiatry 
Consultative/Liai1on 
Psychiatry 
Psychiatric Ambulatory Care 





















Clifford H. Schilke, MD 
Farhad Sholevar, MD 
Joseph L. Antonowicz, MD 
Susan D. Wiley, MD 
Michael W. Kaufmann, MD 
Victor Risch, MD, PhD 
Charles F. Andrews, MD 
Mark A. Osborne, MD 
Robert Kricun, MD 
Robert Kricun, MD 
Alan H. Wolson, MD 
Alan H. Wolson, MD 
Christopher L. Brown, MD 
Christopher L. Brown, MD 
Mark A. Osborne, MD 
James W. Jaffe, MD 
Allen J. Weinstein, DO 
Howard D. Rosenberg, MD 
Z. S. Lin, MD 
Stanley Benzel, MD 
Mark A. Osborne, MD 
Stuart A. Jones, MD 
Herbert C. Hoover, Jr., MD 
William W. Frailey, MD 
Gary G. Nicholas, MD 
Michael Rhodes, MD 
Gary G. Nicholas, MD 
Lester Rosen, MD 
Walter J. Okunski, MD 
Michael Rhodes, MD 
Joseph Levan, MD 
John Pulizzi, MD 
Daniel Para, MD 
Geary L. Yeisley, MD 










Acting Associate Chairperson 
· Associate Vice Chairperson 
Assistant Vice Chairperson 
Gen Surgery Program Director/ 
Education Director 
Colon/Rectal Program Dir ./ 
Research Director 
Plastic Surg. Program Dir. 
Trauma Program Director 
Critical Care Director 
Assocjate Chief 
Farrokh S. Sadr, MD 


















TrMJma-surgical Critical Care 
Trauma 






Gerald Sherwin, MD 
Chris C. Chang, MD 
Craig Reckard, MD 
Mark C. lester, MD 
Zev Elias, MD 
(Vacant) 
Ronald Dileo, DDS 
Peter A. Keblish, MD 
Patrick Respet, MD 
David P. Steed, DPM 
John D. Harwick, MD 
Walter J. Okunski, MD 
Michael Rhodes, MD 
Mark Cipolla, MD 
Michael Pasquale, MD 
Kevin J. Farrell, MD 
Richard M. Lieberman, MD 
Alan Berger, MD 
Mark Gittleman, MD 
Robert A. Morrow, MD 
Mark Grim, DMD 
Peter M. Anson, MD 
John Papola, MD 
Geoffrey G. Hallock, MD 
(Associate Chief) 
(Associate Chief) 
Walter J. Okunski, MD 
Edward M. Mullin, MD 
Victor J. Celani, MD 
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LEHIGH VALLEY HOSPITAL 
1995-1996 
UNIT DIRECTORS 
(Effective July 1, 1995) 
Medical Critical Care Director- Richard H. Snyder, MD 
Surgical Critical Care Director - Michael Rhodes, MD 
C«hhr Cnl•t & 1-78 Site 
Acute Care Unit 
Burn Unit 
Central Nervous System Unit 
Dialysis 
Medical Intensive Care Unit 
Open Heart Unit 
Progressive Coronary Care Unit 
Post Anesthesia Care Unit 
Special Care Unit 
Shock Trauma Unit 
Surgical Intensive Care Unit 
Transitional Open Heart Unit 
Transitional Trauma Unit 
3C 










-Norman Sarachek, MD 
- Walter Okunski, MD/Kevin Farrell, MD 
-George Chovanes, MD 
-James Kintzel, MD 
-Jay Kaufman, MD 
-Geary Yeisley, MD 
- Norman Marcus, MD 
- Karen Bretz, MD 
- Jay Cowen, MD (Medical Director) 
- Michael Rhodes, MD 
-Michael Pasquale, MD 
- Brian Kluck, DO 
-Michael Pasquale, MD 
- Bruce Feldman, DO 
- Robert Oriel, MD 
- Kenneth McDonald, MD 
-Michael Sinclair, MD 
-Richard Boorse, MD 
- Peter Keblish, MD 
- Mark Lester, MD 
- Paul Guillard, MD 
-(Vacant) 
-David Caccese, MD 
- Robert Grunberg, MD 
-John Nuschke, MD 
-Glenn Short, MD (Co-Director) 





17th & Chew Site 
Ambulatory Surgery Unit 
High Risk Perinatal Unit 
Intensive Care Unit 
Labor & Delivery Room 
Mother/Baby 
Neonatal Intensive Care Unit 
Observation Nursery 
Pediatric Ambulatory Surgery Unit 
Post Anesthesia Care Unit 










Adult Partial Hospitalization Program 
Guidance Program 
Transitional Living Center 
-Alphonse Maffeo, MD 
- Walter Okunski, MD 
- James Balducci, MD 
- (Vacant) 
-James Balducci, MD 
-James Balducci, MD 
- Jan Gertner, MD 
-Jan Gertner, MD 
- lan Gertner, MD 
- John Harwick, MD 
- Karen Bretz, MD 
-David P. Carney, MD (Co-Director) 
-Howard A. Silverman, MD (Co-Director) 
- Vincent Lucente, MD 
- Claire Bolon, MD 
- John Campion, MD 
-Clifford Schilke, MD 
- Farhad Sholevar, MO 
-James Showalter, MD 
- Ralph Primelo, MD 
- Susan Wiley, MD 





LABORATORY AND OTHER SERVICE MEQICAL DIRECTORS 
John & Dorothy Morgan Cancer Center Directors 
Interim Director of the Cancer Center 
Behavioral and Counselling Svc 
Cancer Pathology 
Colon/Rectal Unit 









Physiatry and Rehabilitation 
Pulmonary Oncology 
Radiation Oncology 
Hospital Lab/Service Directors 
Cardiac Cath Lab 
Endocrine Testing Station 
Gl Labs 
MedEvac/Emergency Med Institute -
NeuroDiagnostic Lab 
Pediatric Ambulatory Care 
Pulmonary Lab 
Respiratory Care 
Sleep Disorders Lab 
Vascular Lab 





Flow Cytometry Lab 





Transfusion Medicine & HLA Lab 
6/07/95 
x:\wp80w\cred\unitdir.98 
-Herbert C. Hoover, Jr., MD 
Peggy Showalter, MD 
Michael Scarlata, MD 
lndru Khubchandani, MD 
Mark Gittleman, MD 
George Carr, DMD 
Richard Lieberman, MD 
Edward Mullin, MD 
Sergio Perticucci, MD 
John Harwick, MD 
Thomas Koch, MD 
Surendra S. Shah, MD 
John Margraf, MD 
Mark Lester, MD 
(Vacant) 
Michael Scarlata, MD 
Jane Dorval, MD 
Jonathan Hertz, MD 
Raymond Singer, MD 
Victor Risch, MD, PhD 
Robert Oriel, MD (Director) 
Dean Dimick, MD (Director) 
Carl D'Angelo, MD (Director) 
Robert Riether, MD (Asst. Director) 
John F. McCarthy, DO (Director) 
Alexander Rae-Grant, MD (Director) 
Charles Smith, MD (Director) 
John Galgon, MD (Director) 
John Galgon, MD (Director) 
John Galgon, MD (Co-Director) 
William Pistone, DO (Co-Director) 
William Gee, MD (Director) 
Gerald E. Clement, PhD (Technical Director) 
David Beckwith, PhD (Director) 
William Dupree, MD (Medical Director) 
Gerald E. Clement, PhD (Technical Director) 
David G. Beckwith, PhD (Co-Director) 
(Vacant) (Co-Director) 
David Prager, MD (Medical Director) 
Gerald E. Clement, PhD (Technical Director) 
David G. Beckwith, PhD (Technical Director) 
(Vacant) (Division Director) 
Gerald E. Clement, PhD (Technical Director) 






P & T HIGHLIGHTS 
The following action were taken at the May 19, 1995 Pharmacy 
and Therapeutics Committee Meeting- Maria Barr, Pharm.D., 
Barbara Leri, Pharm.D., Richard Townsend, R.Ph., M.S. 
COMMITTEE MEMBERSHIP 
EXPANDS 
The Pharmacy and Therapeutics Committee 
approved the membership additions of a 
clinical nutritionist and a medical and 
surgical resident as well as expansion of 
internal medicine representation. 
AZITHRO REPLACES 
CLARITHRO AT L VH 
Azithromycin (Zithromax, Pfizer) has been 
added to our formulary and will replace 
clarithromycin as an oral antimicrobial agent 
for use in a wide variety of infections. 
Azithromycin is an azalide antibiotic 
structurally different than the macrolides 
clarithromycin and erythromycin. The 
structural difference allows for greater tissue 
penetration and concentrations. Physicians 
are urged to remember that Erythromycin is 
still a viable cost-effective option in some 
cases. 
The Committee approved the addition of 
azithromycin based on the following 
advantages: 1) shorter length of therapy of 
5 days; 2) high tissue concentrations; and 3) 
single dose therapy for nongonococcal 
urethritis and cervicitis. Beginning July 1, 
all clarithromycin orders on patient greater 
than 18 years old who are not being treated 
for MAl, will be automatically substituted 
with a 5 day course of azithromycin. The 
dose of azithromycin is 250mg BID on day 
1, followed by 250mg once daily on days 2 
through 5. In the treatment of sexually 
transmitted disease, a single dose of 1000mg 
is effect. 
The average cost of therapy based on 
hospital acquisition cost for 5 days of 
azithromycin is $29.04. Clarithromycin 
500mg BID for a 10 day course is $46.40. 
FINALLY .•. A VACCINE TO 
PREVENT CHICKENPOX 
The committee approved addition of 
Varicella Virus Vaccine to the formulary. 
The vaccine, marketed by Merck under the 
brand name Varivax contains live, 
attenuated virus. Anticipated efficacy of the 
vaccine is 70-90%. The duration of 
protection against varicella virus is 
unknown. Postmarketing studies will be 
conducted to determine long term efficacy 
and the need for subsequent boosters. 
The vaccine is approved by the FDA for use 
in patients 12 months of age and older. The 
recommended dose for patients 12 months to 
12 years of age is a single 0.5 ml dose given 
subcutaneously. Patients 13 years and up 
should receive two 0. 5 ml doses given four 
to eight weeks apart. The American 
Academy of Pediatrics recommends that the 
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vaccine be given routinely to healthy 
children at 12 to 18 months of age. The 
academy also recommends immunization of 
children 18 months to 13 years of age who 
have not had chickenpox. The vaccine 
should not be given to patients who are 
pregnant, immunosuppressed, or who have 
untreated tuberculosis, febrile 'infective 
illnesses, blood dyscrasias, or malignancies · 
affecting the bone marrow or lymphatic 
system. Varicella can be administered at the 
same tiute as other routine pediatric 
immunizations. Administration of varicella 
vaccine should be delayed at least 5 months 
after receiving blood products, immune 
globulin, or varicella zoster immune 
globulin. Vaccine recipients should avoid 
use of salicylates for 6 weeks post-
immunization due to reports of the 
development of Reye' s Syndrome in patients 
with natural varicella infection who were 
given aspirin. 
The acquisition cost of varicella vaccine is 
$39.94 per dose. Contact Clinical Pharmacy 
Services (CC-#8884, 17-#2797) for 
additional information. 
GLUCOPHAGE . .• THE 
SUCCESSOR OF PHENFORMIN 
A recently approved agent, Glucophage 
(MetforminR, Bristol-Myers Squibb), was 
reviewed for addition to the formulary. It is 
a non-sulfonylurea which may be used alone 
as an adjunct to diet or in combination with 
a sulfonylureas which are not adequately 
controlling blood sugars in NIDDM. 
Glucophage improves glucose tolerance in 
NIDDM patients by lowering both the basal 
and postprandial plasma glucose. 
Glucophage works differently compared to 
the sulfonylureas through a decrease in 
hepatic glucose production, a decrease in 
intestinal absorption of glucose and 
improvement of insulin sensitivity. 
Hypoglycemia does not result from 
glucophage therapy, adding to the advantage 
of this agent. 
Approval of this medication was tabled 
following concerns related to the potential 
adverse effects of glucophage, especially 
lactic acidosis. Lactic acidosis, though rare, 
can occur secondarily to accumulation of 
glucophage. When it occurs, it is fatal in 
50% of the cases. Reported cases have 
occurred primarily in diabetic patients with 
significant renal insufficiency. The risk of 
lactic acidosis increases with the degree of 
renal dysfunction and the patient's age. Due 
to impaired hepatic function, the body may 
not be able to adequately clear lactate. 
Patients should be cautioned against 
excessive alcohol intake while receiving 
metformin due to alcohol's ability to 
potentiate the effect of glucophage on lactate 
metabolism. 
Glucophage is considered to be 
contraindicated in patients with renal disease 
or renal dysfunction, suggested by a serum 
creatinine of .L 1.5mg/dl. The drug should 
be temporarily withheld (at least 48 hours 
prior to and 48 .hours after procedure) in 
patients undergoing radiologic studies 
involving parenteral contrast dyes due to the 
possibility of acute changes in renal 
dysfunction with the use of these agents. 
Finally, the drug should be withheld in 
patients with any type of hypersensitivity to 
metformin or have an underlying chronic 
metabolic acidosis including diabetic 
ketoacidosis with or without coma. 
Many precautions exist for glucophage, 
some of which include the monitoring of 
renal function, concomitant use of other 
medications which alter renal function 




In addition to lactic acidosis, other potential 
adverse effects include gastrointestinal 
reactions, alteration of taste and 
asymptomatic subnormal vitamin B12 levels. 
The usual starting dose for glucophage is 
500mg PO BID administered with the 
morning and evening meal with dosage 
increments of one tablet every week to a 
maximum of 2550mg/day. This usual 
maintenance dose is 850mg PO BID. 
Monitoring of glycosolated hemoglobin 
should occur approximately every three 
months. Fasting plasma glucose should be 
used to determine the therapeutic response 
to glucophage. 
The expected costs of this agent will range 
from $0.70 to $1.95/day. 
Further discussion will continue during the 
next meeting to discuss glucophage and its 
place in the course of therapy for NIDDM 
patients. Stay tuned! 
ANTIMICROBIAL COST REPORT 
SHOWS A DOWN TREND FROM 
1993 
Antimicrobial drug costs comprise 
approximately 14% of our total 
pharmaceutical budget. This is an area with 
several options for cost containment. The 
Committee has approved several pharmacy 
initiated interventions to help control the 
antimicrobial budget including IV to PO 
conversions, renal dosing, and more 
effective dosing options in select cases. 
The following graph illustrates the 
antimicrobial total costs per month from 
May 1993 to March 1995. Note the 
downward trend which is statistically 
significant (p = . 03). It is important to note 
that even the average 4% pharmaceutical 
inflation rate per year has not been 
experienced at LVH. Let's keep it up with 
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V ANCO LEVELS - ONLY WHEN 
APPROPRIATE 
Since our initial efforts in May 1993, the 
number and appropriateness of vancomycin 
serum levels has improved drastically. This 
improvement has been associated with a 
substantial cost savings to the laboratory 
department. During the period of January to 
April 1995, 37% vanco levels were 
perfonned. This is a 60% decrease from 
pre May 1993 data. This year to date data 
was associated with approximately 
$9,106.50 in laboratory savings. As a 
reminder the guidelines for vancomycin 
level monitoring are as follows: 
VANCO SERUM LEVELS SHOULD 
NOT BE ROUTINELY DONE IN 
PATIENTS WITH NORMAL RENAL 
FUNCTION AND SUSCEPTIBLE 
ORGANISMS 
Vancomycin trough levels maybe useful (but 
are not mandatory) in the following 
situations: 
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1. Patients receiving combination 
therapy with other nephrotoxic 
agents ie. vancomycin + an 
aminoglycoside (gentamicin, 
tobramycin, or amikacin). 
2. Patients on hemodialysis to aid in 
determining time for next dose (usual 
adult dose is lGM weekly). 
3. Patients in higher-than-usual doses of 
vancomycin being given for resistant 
or CNS infection. 








A Service of IEBJ2HVAI..LEV 
HOSPfDU. 
Transfusion Associated Graft Versus Host Disease (TA-GVIID), an 
Indication to Irradiate Cellular Blood Components 
GVHD occurs due to implantation 
of viable donor T lymphocytes in 
a transfusion recipient (host), 
followed by a clonal proliferation 
and recruitment of other 
lymphocytes via cytokines. The 
donor lymphocytes mount an 
immune response towards the host 
organs. It is a frequent 
occurrence following bone 
marrow transplantation. The 
animal counterpart of this is called 
Runt Syndrome. 
The true incidence of TA-GVHD 
is unknown, although it is 
estimated to be approximately 
0.1 % to 1 % in patients carrying a 
diagnosis of hematological 
malignancies or 
lymphoproliferative disor~ers. 
It is often not recognized because 
the clinical manifestations of TA-
GVHD may be mistakenly 
attributed to the underlying 
disease of the patient or to another 
complication such as a drug 
reaction or an infection (viral or 
bacterial). 
The length of time between 
transfusion and the development 
of GVHD is variable and can be 
as short as 3-10 days. 
Clinical Manifestations - Abrupt 
onset of 
- High fever: (Tumor necrosis 
factor (TNF) and IL-l mediated) 
-Rash Maculopapular: Lymphoid 
infiltration at the dermal epidermal 
junction with basal cell 
degeneration 
- Severe Diarrhea 
- Liver Dysfunction - elevation 












Skin Liver Gastrointestinal 
Tract 
Maculopapular Serum bilirubin > 500 mL 
rash < 25% body 2-3mg/dL diarrbea/d 
surface 
Maculopapular Serum bilirubin > 1000 mL 
rash 25-50% body 3-6mg/dL diarrheald 
surface 
Generalized Serum bilirubin > 1500 mL 
erythroderma 6'"'15mg/dL diarrheald 
Generalized Serum bilirubin Severe abdominal 
erythroderma with > 15 mg/dL 
bullous formation 
and desquamation 
In contrast to bone marrow 
transplant associated GVHD, TA-
GVHD is associated with high 
mortality (80-90%). There is no 
effective treatment although 
methotrexate, cyclosporin and 
steroids have been tried. 
Since the minimum numbers of 
lymphocytes required to cause 
TA-GVHD is not known, the best 
means to avoid TA-GVHD is 
prophylaxis. This is achieved by 
irradiating cellular components 
(red cells, platelets and 
granulocytes). The current 
recommendation is to expose the 
cellular components to 2500 rads 
of gamma irradiation in a 
specially designed canister. This 
eliminates the lymphocyte 
proliferative response (mitogenic 
pain with or 
without ileus 
potential). It has no effect on 
RBC, platelets, or granulocytic 
survival or function. The red 
blood cells demonstrate mild 
irradiation injury by leaking 
potassium. The -mechanism of 
this RBC injury is not known. 
The source of irradiation can be 
Cesium137, Cobalt60 or a linear 
accelerator. Cesium is the 
preferred source because of its 
long half life (30 yr) and high 
energy levels. Most blood 
irradiatiors are self contained units 
with special canister to hold the 
unit of blood. The irradiatiors are 
expensive (approximately 
$100,000). Miller Memorial 
Blood Center serves as our 
regional center to irradiate blood. 
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Therefore, some logistical 
coordination is required, 
particularly between 4 p.m. and 8 · 
a.m. weekdays and on weekends. 
TA-GVHD occurs in both 
(a) Immunocompromised host• 
(b) Immunocompetent host 
•To date TA-GVHD has not been 
reported in HIV infected persons. 
The current indication to irradiate 
cellular blood components as 
practiced. at NIH are as follows. 
At Lehigh Valley Hospital, we are 
also currently following these 
guidelines. 
Absolute Indications 
- Allogenic and autologous 
marrow transplant recipients 
- SCID syndromes 
- Intrauterine transfusions 
-Neonatal exchange transfusions 
- Hodgkin's disease 
-Very high dose alkylating agent 
therapy 
( > 4gm/M2 cyclophosphamide) 
- Related-donor donations (HLA 
sharing or one way HLA match) 
Indications Under Review 
- Premature neonates (birthweight 
< 1200 gm) 
- Non-Hodgkin's lymphoma 
(including chronic lymphocytic 
leukemia) 
- Acute leukemia (including blast 
crisis of chronic myelogenous 
leukemia 
-Neuroblastoma 
- Glioblastoma multiforme 
Not Indicated 
- Aplastic anemia 
- HIV infection/ AIDS 
-Term neonates 
- Solid tumors (except for 
situations listed above) 
If you have any questions, please 
contact Bala B. Carver, MD, 
Medical Director, Transfusion 
Medicine/HLA, at 402-8142. 
John J. Shane, MD 
Chairperson 
Department of Pathology 
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